The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 22, 2019

Filed:

Dec. 18, 2015
Applicants:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Danilo R. Casimiro, Harleysville, PA (US);

Andrew Bett, Lansdale, PA (US);

Beth-ann Griswold Coller, Belle Mead, NJ (US);

Govindarajan Dhanasekaran, Harleysville, PA (US);

Ramesh V. Chintala, Chalfont, PA (US);

Inventors:

Danilo R. Casimiro, Harleysville, PA (US);

Andrew Bett, Lansdale, PA (US);

Beth-Ann Griswold Coller, Belle Mead, NJ (US);

Govindarajan Dhanasekaran, Harleysville, PA (US);

Ramesh V. Chintala, Chalfont, PA (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/12 (2013.01); C12N 7/00 (2013.01); A61K 2039/5252 (2013.01); A61K 2039/5254 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55505 (2013.01); A61K 2039/55577 (2013.01); A61K 2039/575 (2013.01); A61K 2039/70 (2013.01); C12N 2770/24122 (2013.01); C12N 2770/24134 (2013.01); C12N 2770/24171 (2013.01); Y02A 50/386 (2018.01);
Abstract

The present invention relates to dengue virus vaccine compositions comprising a first and a second dengue vaccine, wherein the first dengue vaccine comprises at least one live, 5 attenuated dengue virus or live, attenuated chimeric dengue virus and the second dengue vaccine is a recombinant dengue subunit vaccine, a DNA vaccine, a conjugate vaccine, or an inactivated dengue vaccine; wherein the genome of the live attenuated dengue virus or the live attenuated chimeric dengue virus comprises a 30 nucleotide deletion of the TL2 stem-loop structure of the 3' untranslated region. The dengue virus vaccine compositions of the invention may further 10 comprise one or more adjuvants. In preferred embodiments of the invention, the first and the second dengue vaccine are tetravalent. The invention also relates to methods of using the dengue virus vaccine compositions of the invention to treat or prevent dengue infection, or to prevent, ameliorate, or delay the onset or progression of the clinical manifestations thereof.


Find Patent Forward Citations

Loading…